In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Stada Grows In Russia And CIS With Takeda Deal

Stada To Pay $660m For 20 OTC And Prescription Brands

Executive Summary

Stada will pay $660m for a basket of 20 brands from Takeda to expand its consumer health portfolio in Russia and a number of strategically important CIS markets.

You may also be interested in...



Stada Will Continue To Invest To Drive Growth

After a 12-month period that has seen Stada make significant investments in generics, biosimilars and consumer healthcare, CEO Peter Goldschmidt tells Generics Bulletin that the firm does not intend to stop there, as it pursues both organic and inorganic growth opportunities.

Nidda Will Squeeze Out Remaining Stada Shares

Stada’s owner has revealed plans to squeeze out the German firm’s remaining minority shareholders.

Sandoz’ Eder Heads Russia For Stada

Stada has announced the appointment of former Sandoz Germany head Stephan Eder to lead its business in Russia and the CIS. The appointment comes as Stada has just closed a $660m consumer healthcare acquisition with Takeda in the region.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1127945

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel